Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3925077 | 0.84 | POLB (0.43) | ALDH1A1POLBSMN1; SMN2L3MBTL1HSD11B1 | |
| SCHEMBL31344705 | 0.82 | HSD11B1 (0.44) | ALDH1A1POLBL3MBTL1HSD11B1GABRA1 | |
| SCHEMBL12779601 | 0.82 | GABRA1 (0.53) | ALDH1A1POLBSMN1; SMN2HTTMCL1 | |
| SCHEMBL799370 | 0.82 | POLB (0.42) | ALDH1A1POLBSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL21566643 | 0.79 | POLB (0.41) | POLBL3MBTL1HSD11B1 | |
| SCHEMBL9379437 | 0.79 | HSD11B1 (0.54) | POLBSMN1; SMN2L3MBTL1HSD11B1GABRA1 | |
| SCHEMBL1106525 | 0.77 | L3MBTL1 (0.52) | POLBL3MBTL1HSD11B1GABRA1GABRB2 | |
| SCHEMBL1415493 | 0.75 | L3MBTL1 (0.46) | ALDH1A1POLBSMN1; SMN2L3MBTL1HSD11B1 | |
| SCHEMBL22927502 | 0.75 | HSD11B1 (0.47) | POLBSMN1; SMN2L3MBTL1HSD11B1GABRA1 | |
| SCHEMBL29617 | 0.75 | HSD11B1 (0.47) | ALDH1A1POLBSMN1; SMN2L3MBTL1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
| US-9790229-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9249146-B2 | Bruton'S tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9206142-B2 | Anilinopiperazine derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9029359-B2 | Heteroaryl Btk inhibitors | BIOGEN IDEC MA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-10-16 | — | — | US | disclosed |
| US-8785440-B2 | Bruton's tyrosine kinase inhibitors | BIOGEN IDEC MA, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120328691-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2012-12-27 | — | — | US | disclosed |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011029043-A1 | HETEROARYL BTK INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011029046-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | BTK, LYN, SYK | ALDH1A1 4759/4885POLB 2653/4885SMN1; SMN2 4798/4885 |
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ALDH1A1 4783/4885POLB 1897/4885SMN1; SMN2 4292/4885 |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ALDH1A1 4783/4885POLB 1897/4885SMN1; SMN2 4292/4885 |
| US-20120328691-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MAPK15, CDK15, MAPKAPK5 | ALDH1A1 3548/4885POLB 2161/4885SMN1; SMN2 3649/4885 |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ALDH1A1 4783/4885POLB 1897/4885SMN1; SMN2 4292/4885 |
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | ALDH1A1 4783/4885POLB 1897/4885SMN1; SMN2 4292/4885 |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ALDH1A1 4783/4885POLB 1897/4885SMN1; SMN2 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.